Amoxicillin Global Market Report 2024

Amoxicillin, a member of the penicillin group, is a broad-spectrum antibiotic used for treating a wide range of bacterial infections. Its mechanism involves inhibiting bacterial growth by preventing the formation of cell walls. This effectively combats infections including respiratory tract infections, urinary tract infections, skin infections, and certain types of bacterial endocarditis.

Amoxicillin belongs to the main drug classes of antibiotics such as penicillins, cephalosporins, tetracyclines, macrolides, and sulfonamides. Penicillins are derived from the Penicillium mold and share a core structure. The drug is available in various formulations including tablets, capsules, suspensions, syrup, and powder. It is used for treating infections such as skin infections, ear, nose, and throat infections, gastrointestinal infections, pulmonary infections, urinary tract infections (UTIs), pneumonia, bronchitis, and gonorrhea. These treatments are utilized across different settings including hospitals, homecare, specialty clinics, and other healthcare facilities.

The amoxicillin market research report is one of a series of new reports that provides amoxicillin market statistics, including amoxicillin industry global market size, regional shares, competitors with amoxicillin market share, detailed amoxicillin market segments, market trends and opportunities, and any further data you may need to thrive in the amoxicillin industry. This amoxicillin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The amoxicillin market size has grown steadily in recent years. It will grow from $4.58 billion in 2023 to $4.74 billion in 2024 at a compound annual growth rate (CAGR) of 3.4%. The growth observed in the historical period can be credited to enhanced knowledge of antibiotics, accelerated research activities and developments, increased occurrences of cardiovascular diseases, rising demand for amoxicillin in treating urinary tract infections, and a growing elderly population.

The amoxicillin market size is expected to see steady growth in the next few years. It will grow to $5.44 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period is driven by factors such as increasing incidence of impaired renal function, higher prevalence of lower respiratory infections, rising cases of skin infections, growing occurrences of lower respiratory tract infections, and increasing prevalence of bacterial infections. Key trends expected during this period include a surge in demand for generic amoxicillin, focus on combination therapies, interest in probiotics and immunotherapy, rising demand for antibiotics, and advancements in healthcare facilities.

The rising prevalence of infectious diseases is anticipated to drive the growth of the amoxicillin market in the coming years. Infectious diseases, caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, are becoming more common due to factors such as global travel, antimicrobial resistance, climate change affecting disease vectors, and higher population density. Amoxicillin is effective in treating these diseases by targeting bacterial cell wall synthesis, leading to bacterial cell death. Its broad-spectrum activity, rapid absorption, and ability to work synergistically with other antibiotics make it a versatile and effective treatment for various bacterial infections. For example, in January 2023, the National Institute of Health reported that urinary tract infections ranked seventh among the leading reasons for emergency department visits in the US, accounting for over 1 million visits annually. Of these, 22% (220,000) were classified as complicated UTIs, with approximately 100,000 cases resulting in hospital admissions each year. Consequently, the increasing prevalence of infectious diseases is fueling the growth of the amoxicillin market.

The increase in healthcare expenditure is expected to drive the growth of the amoxicillin market in the future. Healthcare expenditure refers to the total money spent on healthcare goods and services, including medical treatments, medications, hospitalizations, and preventive care, within a specific period. This expenditure reflects the overall cost of healthcare provision within a population. The rising healthcare expenditures are due to the increasing costs of advanced medical technologies, aging populations, and the prevalence of chronic diseases. Increased healthcare expenditure benefits amoxicillin by ensuring wider accessibility and availability, leading to higher prescription rates and improved patient outcomes. Enhanced funding also supports research and development, potentially leading to better formulations and broader usage of the antibiotic. For example, in January 2024, the National Institutes of Health reported that healthcare expenditure in the US rose by 4.1% in 2022 to reach $4.5 trillion, marking a faster growth rate compared to the 3.2% increase observed in 2021. Thus, the increase in healthcare expenditure is driving the growth of the amoxicillin market.

Major companies in the amoxicillin market are developing innovative drugs, such as reformulated versions of vonoprazan tablets, to enhance the treatment of Helicobacter pylori infections and improve patient outcomes. Vonoprazan is a novel potassium-competitive acid blocker (PCAB), a new class of acid suppressant medication. For example, in May 2022, Phathom Pharmaceuticals, a US-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for VOQUEZNA TRIPLE PAK (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA DUAL PAK (vonoprazan, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection in adults. These treatment regimens include antibiotics conveniently packaged with vonoprazan, a novel potassium-competitive acid blocker (PCAB), marking the first innovative acid suppressant from a new drug class approved in the U.S. in over 30 years.

Major companies operating in the amoxicillin market are Pfizer Inc., Sanofi S.A., AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Merck KGaA, Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Sun Pharmaceutical Industries Ltd., CSPC Pharmaceutical Group Limited, Torrent Pharmaceuticals GmbH, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Lupin Limited, Daewoong Pharmaceutical Co. Ltd., Centrient Pharmaceuticals, Wockhardt Limited, Ranbaxy Laboratories Ltd., Atman Pharmaceuticals, Sinopharm Weiqida Pharmaceutical Co. Ltd., Cipla Inc., Zydus Cadila.

North America was the largest region in the amoxicillin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the amoxicillin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the amoxicillin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The amoxicillin market consists of sales of oral formulations, liquid formulations, extended-release tablets, and specialty products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.